Drugs / hCT-MSC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03473301 | Apr 2018 → Feb 2020 | cerebral palsy | Joanne Kurtzberg, MD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCT-MSC | “AIM: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in...” PMID 35811372 ↗ Jul 2022 |
| Known as | Infusion of MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03473301 ↗ |
| Modality | Cell therapy | “Unrelated donor allogeneic umbilical cord blood (AlloCB) and human umbilical cord tissue-derived mesenchymal stromal cell infusion is safe in young children with cerebral palsy.” PMID 35811372 ↗ Jul 2022 |
| Route | Intravenous | “Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors” NCT03473301 ↗ |